A loss of antigen-specific T-cell responses due to defective cytokine signaling during infections has not been reported. We hypothesize that tuberculosis can destroy signaling effects of selective cytokine(s) and induce exhaustion of antigen-specific T cells. To test this hypothesis, mechanistic studies were performed to examine whether and how tuberculosis blocked interleukin 23 (IL-23) and interleukin 2 (IL-2) signaling effects on a major human γδ T-cell subpopulation, phosphoantigen HMBPP-specific Vγ2Vδ2 T cells. IL-23 and IL-2 significantly expanded HMBPP-stimulated Vγ2Vδ2 T cells from subjects with latent tuberculosis infection, and IL-2 synergized the effect of IL-23. IL-23-induced expansion of Vγ2Vδ2 T cells involved STAT3. Surprisingly, patients with tuberculosis exhibited a selective destruction of IL-23-induced expansion of these cells. The tuberculosis-driven destruction of IL-23 signaling coincided with decreases of expression and phosphorylation of STAT3. Interestingly, impairing of STAT3 was linked to marked increases in the microRNAs (miRNAs) hsa-miR-337-3p and hsa-miR-125b-5p in Vγ2Vδ2 T cells from patients with tuberculosis. Downregulation of hsa-miR-337-3p and hsa-miR-125b-5p by miRNA sponges improved IL-23-mediated expansion of Vγ2Vδ2 T cells and restored the ability of these cells to produce anti-tuberculosis cytokines. These results support our hypothesis that tuberculosis can selectively impair a cytokine effect while sparing another and can induce exhaustion of T cells in response to the respective cytokine.
A loss of antigen-specific T-cell responses due to defective cytokine signaling during infections has not been reported. We hypothesize that tuberculosis can destroy signaling effects of selective cytokine(s) and induce exhaustion of antigen-specific T cells. To test this hypothesis, mechanistic studies were performed to examine whether and how tuberculosis blocked interleukin 23 (IL-23) and interleukin 2 (IL-2) signaling effects on a major human γδ T-cell subpopulation, phosphoantigen HMBPP-specific Vγ2Vδ2 T cells. IL-23 and IL-2 significantly expanded HMBPP-stimulated Vγ2Vδ2 T cells from subjects with latent tuberculosis infection, and IL-2 synergized the effect of IL-23. IL-23-induced expansion of Vγ2Vδ2 T cells involved STAT3. Surprisingly, patients with tuberculosis exhibited a selective destruction of IL-23-induced expansion of these cells. The tuberculosis-driven destruction of IL-23 signaling coincided with decreases of expression and phosphorylation of STAT3. Interestingly, impairing of STAT3 was linked to marked increases in the microRNAs (miRNAs) hsa-miR-337-3p and hsa-miR-125b-5p in Vγ2Vδ2 T cells from patients with tuberculosis. Downregulation of hsa-miR-337-3p and hsa-miR-125b-5p by miRNA sponges improved IL-23-mediated expansion of Vγ2Vδ2 T cells and restored the ability of these cells to produce anti-tuberculosis cytokines. These results support our hypothesis that tuberculosis can selectively impair a cytokine effect while sparing another and can induce exhaustion of T cells in response to the respective cytokine.
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While T cells play important roles in immunity against infections with intracellular pathogens, chronic antigen exposures in certain infections have been shown to induce exhaustion of antigen-specific T cells [1] [2] [3] . Immune interventions for reversing the exhaustion pathway, such as suppression of programmed cell death 1 (PD-1), have been proven somehow successful in certain cancers [4] and infections [5] . However, it is still unclear whether impaired cytokine signaling can cause a loss of antigen-specific T-cell responses. Tuberculosis has recently become the top killer among infectious diseases, owing to the epidemic of human immunodeficiency virus infection and the emergence of multidrugresistant M. tuberculosis [6] . It is important to note that the majority of humans exposed to M. tuberculosis can develop protective immunity against primary infection and that only a small portion of remaining bacilli are needed to cause latent tuberculosis infection (LTBI) [7] . While cell-mediated immunity appears to be important for antituberculosis immunity, the protection may be linked to αβ T-cell populations and unconventional T cells, including the phosphoantigen-specific primate γδ T-cell subset [8, 9] . It has recently been postulated that M. tuberculosis infection may exhaust protective antigen-specific T-cell populations during the development of tuberculosis. While data for tuberculosis exhaustion of antigen-specific T cells are inconsistent [3, [10] [11] [12] , we hypothesize that tuberculosis can impair signaling effects of selective cytokine(s) and blunt or exhaust antigen-specific T-cell responses to the respective cytokine.
The Vγ2Vδ2 T-cell subpopulation exists only in primates and constitutes 60%-95% of the total number of circulating human γδ T cells [13, 14] . Vγ2Vδ2 T cells are the sole γδ T-cell subset capable of recognizing phosphoantigens, such as isoprenoid pyrophosphate and (E )-4-hydroxy-3-methyl-but-enyl pyrophosphate (HMBPP), produced by M. tuberculosis and other selected pathogens [15] . Expansion and differentiation of Vγ2Vδ2 T cells by phosphoantigen plus interleukin 2 (IL-2) therapy administered during the early phase of M. tuberculosis infection can confer resistance against tuberculosis in nonhuman primates [16] . Immunologically, while IL-2, interleukin 15, or interleukin 21 (IL-21) can expand HMBPP-stimulated Vγ2Vδ2 T cells [17] , T-helper type 17 (Th17)-related cytokines, especially interleukin 23 (IL-23), can help induce recall-like expansion and the effector function of HMBPP-specific Vγ2Vδ2 T cells [18] . Given the possibility that the frequency of cells in the HMBPP-specific Vγ2Vδ2 T-cell subset is higher during mycobacterial infection than the frequencies of single M. tuberculosis peptide-specific CD4 + or CD8 + T-cell subpopulations [15] , we presume that tuberculosis-induced exhaustion of Vγ2Vδ2 T cells at the cytokine level would be more readily seen than in other cells in patients with tuberculosis [19] [20] [21] . Since IL-2 or IL-23 could expand HMBPP-specific Vγ2Vδ2 T cells, we sought to determine whether and how tuberculosis could destroy the effects of IL-2 and IL-23 signaling and induce exhaustion of this T-cell subpopulation.
MATERIALS AND METHODS

Ethics Statement
The protocols for use of human blood samples for in vitro experimental procedures were evaluated and approved by the institutional review boards for human subjects research and institutional biosafety committees at Institut Pasteur of Shanghai, Shanghai Pulmonary Hospital, and the University of Illinois-Chicago College of Medicine. All studies were consistent with guidelines of Office for Human Research Protections. All subjects are adults and signed written informed consents.
Human Subjects
Patients with tuberculosis were recruited at Shanghai Pulmonary Hospital (Shanghai, China; Table 1 ). Age-and sexmatched volunteer healthy controls (HCs) and subject with LTBI were recruited into this study (Table 1) .
Peripheral Blood Mononuclear Cell (PBMC) Isolation and Expansion of Vγ2Vδ2 T Cells by HMBPP Plus IL-2 or IL-23
PBMCs were isolated from ethylenediaminetetraacetic acidtreated blood, using a technique previously described by us [22] . Cells were cultured in the absence or presence of 80 ng/mL of HMBPP with 5 ng/mL hIL-2 (Sigma-Aldrich) or 100 ng/mL hIL-23 (R&D Systems, Minneapolis, MN). In special treatments, the following antibodies were used: antihuman IL-2 (clone MQ1-17H12; BD), mouse anti-human PD-1 (clone EH12.2H7; Biolegend), mouse immunoglobulin G2a (IgG2a), κ chain (Isotype, BD); goat anti-human PD-1 (R&D Systems); and goat IgG (Isotype, R&D Systems). The PD-1 antibodies can restore PD-1-associated exhaustion of T cells [23, 24] . Cucurbitacin I (CUI; Sigma-Aldrich) was used for STAT3-targeted blockade experiments.
Flow Cytometry
Flow cytometry was performed as we previously described [18, 22] . The following antibodies were used: anti-CD3-PB (clone SP34-2; BD), anti-Vγ2-FITC (clone 7A5; Pierce), anti- 
Measurement of Cytokine Production
PBMCs from patients with tuberculosis, patients with LTBI, or HCs were cultured for 7 days with medium, HMBPP, HMBPP plus IL-2, or HMBPP plus IL-23. The supernatants were collected on day 7 to measure the level of IFN-γ, tumor necrosis factor α (TNF-α), IL-22, or IL-17A by enzyme-linked immunosorbent assays (ELISA; R&D Systems), using a protocol we previously described [25] . RNA were reverse-transcribed into complementary DNA (cDNA) using the kit from Vazyme Biotech (Nanjing, China). The cDNA was added into 2X Syber Green Mastermix (Toyobo, Shanghai, China) to amplify target gene fragment in triplicate reactions for each gene. Negative controls (no cDNA) were prepared in parallel with each run. Sequences of primers were as follows: IL23R, 5′-CTGGCAGCCTTGGAGTT-3′ and 5′-CCCTGTAGAGATGGAAGCAACTG-3′; STAT3, 5′-TTTGAG ACCGAGGTGTATCACC-3′ and 5′-GGTCAGCATGTTGT ACCACAGG-3′; SOCS3, 5′-TTCTGATCCGCGACAGCTC-3′ and 5′-TGCAGAGAGAAGCTGCCCC-3′; Vγ2, 5′-TCAACTG GTACAGGAAGACCCAAG-3′ and 5′-TGACAGCATTGTA CTTCCCACTGG-3′, IFNG, 5′-GCAGGTCATTCAGATGT AGCGG-3′ and 5′-TGTCTT CCTTGATGGTCTCCACAC-3′; IL17A, 5′-CAATCCCACGAAATCCAGGATG-3′ and 5′-GGT GGAGATTCCAAGGTGAGG-3′; and β-actin, 5′-GCCCTGA GGCACTCTTCCA-3′ and 5′-TGTTGGCGTAC AGGTCTTT GC-3′. The β-actin was used as internal control gene for normalization.
Real-Time qPCR for Quantification of microRNA (miRNA) Expression
Total miRNA was extracted from freshly isolated Vδ2 T cells, using the Quick-RNA MicroPrep kit according to the manufacturer's instructions (Zymo Research, CA). Relevant complementary DNA (cDNA) was synthesized with miRcute miRNA First-Strand cDNA Synthesis Kit (Tiangen, Beijing, China). qPCR primers of miR-223-3p, miR-106a-5p, miR-93-5, miR-124-3p, miR-17-5p, miR-223-3p, miR-17-5p, miR-337-3p, miR-125b-5p, U6, and 5s were also purchased from Tiangen. Real-time qPCR was performed by use of the miRcute miRNA q-PCR Detection kit (SYBR Green). The relative expression level of miRNA was normalized by U6 or 5s, and the data from HCs were used as calibrator. Lentiviral vectors containing a gene encoding enhanced green fluorescence protein (EGFP) were used to develop miRNA constructs to achieve high-efficiency introduction of miRNA into cells. Recombined pCMV-LV-GV234-GFP vectors bearing the has-miR-125b-5p (MIMAT0000754) gene (LV-has-125b-5p), the has-miR-337-3p (MIMAT0000423) gene (LV-has-337-3p), or a scrambled control sequence (LV-GV234) were constructed by Genechem (Shanghai In the current study, we hypothesize that tuberculosis can destroy a selected cytokine signal but spare another, leading to nonexpansion or exhaustion of antigen-stimulated T cells. To test this hypothesis, we used the HMBPP-specific Vγ2Vδ2 T-cell subset as a model system. We investigated whether tuberculosis could impair IL-23 or IL-2 signaling and lead to exhaustion of Vγ2Vδ2 T cells at the cytokine level. These 2 cytokines were selected for evaluation on the basis of the observations that IL-23 is involved in recall-like expansion of the primate Vγ2Vδ2 T-cell subset after infections or vaccination [18] and that IL-2 can act as a master T-cell growth factor [25] [26] [27] . As an initial effort, Vγ2Vδ2 T cells from subjects with LTBI were assessed for the ability to expand in coculture with IL - Since both IL-23 and IL-2 signals could expand the HMBPPspecific Vγ2Vδ2 T-cell subset during LTBI, we examined whether tuberculosis could selectively impair one of these two cytokine signals and lead to nonexpansion of Vγ2Vδ2 T cells in response to the respective cytokine plus HMBPP. Interestingly, patients with tuberculosis exhibited selective impairment of the effect of IL-23 on the HMBPP-specific Vγ2Vδ2 T-cell subset, since IL-23 but not IL-2 was unable to induce significant expansion of HMBPP-stimulated Vγ2Vδ2 T cells from patients with tuberculosis, compared with subjects with LTBI and BCGvaccinated HCs ( Figure 2A ). In addition, IL-23/HMBPP costimulation of Vγ2Vδ2 T cells from patients with tuberculosis but not HCs failed to induce effector function for production of the antituberculosis cytokines IFN-γ, TNF-α, IL-17A, and IL-22 ( Figure 2B ). Furthermore, short-term treatment of patients with tuberculosis with tuberculosis drugs could partially restore the ability of Vγ2Vδ2 T cells to mount an effector function for cytokine production in response to IL-23, although such initial therapy did not effectively reconstitute the expansion capability of Vγ2Vδ2 T cells in response to IL-23/HMBPP cocultures ( Figure 2C ). These results suggest that chronic tuberculosis could impair the signaling effect of one single cytokine but spare another, leading to nonexpansion or exhaustion of the HMBPP-specific Vγ2Vδ2 T-cell subpopulation in response to IL-23. experiments. *P < .05 and **P < .01. C, Short-term (ie, 1-month) treatment of patients with tuberculosis with antituberculosis antibiotics did not effectively reconstitute the expansion capability of Vγ2Vδ2 T cells in response to IL-23/HMBPP in vitro (top panels), but such transient therapy partially restored the ability of HMBPP-specific Vγ2Vδ2 T cells to mount an effector function for cytokine production in response to IL-23 (lower panels). Data are means ± SEM, pooled from 20 patients with tuberculosis in 3 independent experiments. *P < .05, **P < .01, and ***P < .001. Abbreviation: NS, not significant.
IL-23/HMBPP-Induced Expansion of Vγ2Vδ2 T Cells Involves STAT3: Vγ2Vδ2 T Cells in Patients With Tuberculosis Showed Decreased Expression and Phosphorylation of STAT3 but Displayed Overexpression of Antagonizing SOCS3
We then sought to explore potential mechanisms underlying the destruction of IL-23-induced expansion of the HMBPPspecific Vγ2Vδ2 T-cell subset. We found that IL-23R expression in Vγ2Vδ2 T cells from patients with tuberculosis was detectable but lower than that for subjects with LTBI or HCs ( Figure 3A and 3B). These levels of IL-23R expression did not appear to fully explain the impairment of the effects of IL-23 signaling on Vγ2Vδ2 T cells during tuberculosis. Moreover, exchange of antigen-presenting cells between subjects with LTBI and patients with tuberculosis could not reconstitute the ability of Vγ2Vδ2 T cells from patients with tuberculosis to undergo expansion in response to the IL-23/HMBPP costimulation ( Figure 3C ). Concurrently, we also found that anti-PD-1 antibodies from 2 resources capable of reversing αβ T-cell exhaustion [29, 30] could not rescue the expansion of Vγ2Vδ2 T cells from patients with tuberculosis in response to IL-23/HMBPP costimulation ( Figure 3D ). Next, we examined which activation molecules were involved in IL-23-induced expansion of γδ T cells and determined whether their dysfunction could be linked to the impairment of IL-23-induced expansion of HMBPP-stimulated Vγ2Vδ2 T cells. It was recently reported that IL-23-mediated expansion of CD4 + T cells mainly uses the JAK2 and Tyk2 pathway for phosphorylating STAT3 [31] [32] [33] and that the [23, 24, 43] . Data are means ± SEM, derived from 18 patients with tuberculosis in 3 independent experiments. **P < .01.
We then sought to explore potential mechanisms underlying the destruction of IL-23-induced expansion of the HMBPPspecific Vγ2Vδ2 T-cell subset. We found that IL-23R expression in Vγ2Vδ2 T cells from patients with tuberculosis was detectable but lower than that for subjects with LTBI or HCs ( Figure 3A and 3B ). These levels of IL-23R expression did not appear to fully explain the impairment of the effects of IL-23 signaling on Vγ2Vδ2 T cells during tuberculosis. Moreover, exchange of antigen-presenting cells between subjects with LTBI and patients with tuberculosis could not reconstitute the ability of Vγ2Vδ2 T cells from patients with tuberculosis to undergo expansion in response to the IL-23/HMBPP costimulation ( Figure 3C ). Concurrently, we also found that anti-PD-1 antibodies from 2 resources capable of reversing αβ T-cell exhaustion [29, 30] could not rescue the expansion of Vγ2Vδ2 T cells from patients with tuberculosis in response to IL-23/HMBPP costimulation ( Figure 3D ). Next, we examined which activation molecules were involved in IL-23-induced expansion of γδ T cells and determined whether their dysfunction could be linked to the impairment of IL-23-induced expansion of HMBPP-stimulated Vγ2Vδ2 T cells. It was recently reported that IL-23-mediated expansion of CD4 + T cells mainly uses the JAK2 and Tyk2 pathway for phosphorylating STAT3 [31] [32] [33] and that the [23, 24, 43] . Data are means ± SEM, derived from 18 patients with tuberculosis in 3 independent experiments. **P < .01.
phosphorylated STAT3 dimer subsequently activates transcription of cytokine-responsive genes in the nucleus [31, 32] (Figure 4A ).
To test whether STAT3 was also involved in IL-23-induced expansion of Vγ2Vδ2 T cells, the STAT3-targeted inhibitor CUI [34] was assessed for the ability to block IL-23/HMBPP- + T cells [33, 44] . Note that the phosphorylated STAT3 dimer subsequently activates transcription of proliferating/cytokine-responsive genes in the nucleus [31, 32] . Below, the STAT3-targeted inhibitor cucurbitacin I (CUI) blocked IL-23-induced expansion of HMBPP-stimulated Vγ2Vδ2 T cells from subjects with latent tuberculosis infection (LTBI). CUI at a concentration of 2 nM significantly reduced IL-23-mediated expansion of HMBPP-stimulated Vγ2Vδ2 T cells but spared the effect of IL-2 signaling on these cells. B, Flow cytometry-based analysis showed that phosphorylation levels of STAT3 at pS727 and pY705 sites in Vγ2Vδ2 T cells were significantly decreased in fresh, unstimulated peripheral blood mononuclear cells (PBMCs) from patients with tuberculosis as compared to healthy controls (HCs). At left are representative flow cytometry-based histograms displaying percentage numbers of Vγ2 + pS727 + cell subpopulation among Vγ2 + T cells in patients with tuberculosis was also significantly lower than that in HCs. In contrast, IL-2/ HMBPP costimulation did not cause significant changes in phosphorylated STAT3 between patients with TB and HCs. PBMCs were stimulated for 3 days with medium, HMBPP, HMBPP plus IL-2, and HMBPP plus IL-23 and then were assessed for percentages of pY705 + pS727 + cells among CD3 + Vγ2 + cells, using flow cytometry. D, Expression levels of STAT3 and SOCS3 genes in Vγ2Vδ2 T cells among patients with tuberculosis and HCs. Vγ2Vδ2 T cells were purified from PBMCs by flow cytometry sorting and subjected to RNA extraction and real-time quantitative polymerase chain reaction analysis. Expression of the STAT3 gene in Vγ2Vδ2 T cells from patients with tuberculosis decreased to 16% of the level seen in Vγ2Vδ2 T cells from HCs. Expression of SOCS3 in Vγ2Vδ2 T cells from TB patients is more than 4 times of that in HCs. Data in panels B-D are means ± standard errors of the mean, pooled from 10 HCs and 10 patients with tuberculosis in 3 independent experiments. *P < .05, **P < .01, and ***P < .001. Abbreviation: DMSO, dimethyl sulfoxide.
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induced expansion of Vγ2Vδ2 T cells from subjects with LTBI. CUI at a concentration of 2 nM significantly reduced IL-23/ HMBPP-induced expansion of Vγ2Vδ2 T cells but spared the effects of IL-2/HMBPP signaling ( Figure 4A ), perhaps because IL-2 signaling differently involves JAK1, JAK3, LCK, and SYK [35] . This result prompted us to address whether expression and phosphorylation of STAT3 in Vγ2Vδ2 T cells were different between subjects with tuberculosis and HCs.
The flow cytometry-based analysis showed that phosphorylation levels of STAT3 at pS727 and pY705 sites with or without stimulation were significantly decreased in Vγ2Vδ2 T cells from patients with tuberculosis as compared to HCs ( Figure 4B) . When assessing the STAT3 response to 72-hour costimulation with IL-23/HMBPP, frequencies of the Vγ2 + pY705 + pS727 + cell subpopulation in patients with tuberculosis were also significantly lower than those in HCs ( Figure 4C ). However, IL-2/ HMBPP costimulation did not uncover any significant difference in phosphorylated STAT3 between patients with tuberculosis and HCs ( Figure 4C ). In parallel, we also measured the expression of the gene encoding STAT3 in Vγ2Vδ2 T cells, using real-time qPCR. The level of expression of the STAT3 gene in Vγ2Vδ2 T cells from patients with tuberculosis was only approximately 16% of that seen in Vγ2Vδ2 T cells from HCs ( Figure 4D) .
Concurrently, we compared SOCS3 gene expression between patients with tuberculosis and HCs, because SOCS3 could inhibit STAT3/JAK pathway via binding to JAK2 and negatively regulate cytokine production [36, 37] . Vγ2Vδ2 T cells from patients with tuberculosis showed >4 times greater expression of SOCS3 than those from HCs ( Figure 4D ). This represents additional data supporting the notion that tuberculosis might impair the JAK2/STAT3 activation pathway in Vγ2Vδ2 T cells.
Taken While miRNAs represent a class of bioactive molecules capable of regulating gene expression [38] , some miRNAs have been shown to correlate closely with the STAT3 activation pathway [39] . We therefore sought to determine whether tuberculosis could lead to increased expression of miRNAs that interfere with the STAT3 activation pathway in Vγ2Vδ2 T cells. Interestingly, we found that Vγ2Vδ2 T cells from patients with tuberculosis expressed levels of hsa-miRNA-337-3p and hsa-miRNA-125b-5p that were approximately 6 times higher than those expressed by Vγ2Vδ2 T cells from HCs ( Figure 5A ). Thus, while hsa-miR-337-3p and hsa-miRNA-125b-5p have been shown to downregulate STAT3 gene expression [39] , marked increases in these 2 miRNAs in Vγ2Vδ2 T cells from patients with tuberculosis correlated with low expression or phosphorylation of STAT3.
Next, we conducted a proof-of-concept study to explore a connection between M. tuberculosis infection and increased expression of miRNAs. Interestingly, mycobacterial infection of host cells significantly increased the expression of hsa-miR-337-3p and hsa-miRNA-125b-5p ( Figure 5B ). These results might help explain the increases in these miRNAs seen in the γδ T-cell subset from patients with tuberculosis. Figure 5 . Impairment of the STAT3 pathway coincided with marked increases in hsa-miR-337-3p and hsa-miR-125b-5p expression in Vγ2Vδ2 T cells from patients with tuberculosis. A, Among the microRNAs (miRNAs) capable of targeting STAT3 expression, hsa-miR-337-3p and hsa-miRNA-125b-5p were upregulated by approximately 6-fold in Vγ2Vδ2 T cells from patients with tuberculosis, compared with those from healthy controls (HCs). Expression of 2 other STAT3-targeted miRNAs, hsa-miR-124-3p and has-miR-223-3p, was also increased, although individual variations were seen. Total miRNA was extracted from freshly purified Vδ2 + T cells. The relative expression level of miRNAs was measured by real-time quantitative polymerase chain reaction (qPCR) analysis and normalized by U6 or 5s. BCG-vaccinated HCs were used as a calibrator. Data are means ± SEM standard errors of the mean (SEM), pooled from 16 patients with tuberculosis and 16 HCs in 3 independent experiments. **P < .01. B, Mycobacterial infection of human cells significantly increased the expression of hsa-miR-337-3p and hsa-miRNA-125b-5p. Human A549 cells were infected with Mycobacterium bovis BCG and assessed for expression of miRNAs, using real-time qPCR analysis. Data are fold changes expressed as means ± SEM. ***P < .001.
Silencing of hsa-miR-337-3p and hsa-miR-125b-5p by miRNA Sponges Could Improve IL-23-Mediated Expansion of HMBPP-Stimulated Vγ2Vδ2 T Cells in Patients With Tuberculosis and Restore the Ability of These Cells to Produce Cytokines Given the tuberculosis-driven increases in hsa-miR-337-3p and hsa-miR-125b-5p expression, we investigated the possibility that these STAT3-targeted miRNAs help to impair the STAT3 activation pathway and selectively destroy IL-23-induced expansion of HMBPP-stimulated Vγ2Vδ2 T cells in patients with tuberculosis. To test this hypothesis, we used the pCMV-LV-GV234-GFP lentiviral vector system and developed LV-hsa125b-5p and LV-hsa-337-3p sponge constructs to manipulate decreases in hsa-miR-337-3p and/or hsa-miRNA-125b-5p expression in Vγ2Vδ2 T cells. When the transduction of these miRNA sponges proved successful (Figure 6A) , we found that a combination of LV-hsa-125b-5p and LV-hsa-337-3p but not controls could significantly improve IL-23-induced expansion of HMBPP-stimulated Vγ2Vδ2 T cells in PBMCs from patients with tuberculosis (P = .013136; Figure 6B ). Such improvement or restoration was also seen at the gene-expression level of the Vγ2 T-cell receptor ( Figure 6C ). Furthermore, LV-hsa-125b-5p and LV-hsa-337-3p sponges but not controls reconstituted the ability of IL-23/HMBPP-stimulated Vγ2Vδ2 T cells to express the antituberculosis cytokines IFN-γ and IL-17A ( Figure 6C) . Consistently, immunohistochemical staining followed by flow cytometry analyses showed that the combined miRNA sponges significantly increased the production of IL-17A and IFN-γ by Figure 6 . Downregulation of hsa-miR-337-3p and hsa-miR-125b-5p by microRNA (miRNA) sponges improved the interleukin 23 (IL-23)-mediated expansion of HMBPP-stimulated Vγ2Vδ2 T cells in patients with tuberculosis and restored the ability of these cells to produce cytokines. The pCMV-LV-GV234-GFP vector system was used to develop LVhas-125b-5p, LV-has-337-3p, and control miRNA sponge constructs to manipulate decreases in hsa-miR-337-3p and/or hsa-miRNA-125b-5p expression in Vγ2Vδ2 T cells. A, Microscopic fluorescence (left) and optical (right) pictures show that most peripheral blood mononuclear cells (PBMCs) containing Vγ2Vδ2 T cells give rise to green fluorescent protein-associated florescence after transduction with the miRNA sponges. B, Representative flow cytometry-based histograms (left panels) and bar graph data (right panel) show that transduction with a combination of LV-has-125b-5p and LV-has-337-3p but not controls significantly improved IL-23-induced expansion of HMBPP-stimulated Vγ2Vδ2 T cells in PBMCs from 12 patients with tuberculosis in 4 independent experiments (mean values [ ± SD] were 10.89% ± 1.17% for LV-has-125b-5p and LV-has-337-3p and 7.86% ± 2.08% for control; P = .013136). C, Transduction with LV-has-125b-5p and LV-has-337-3p combined also restored increases in the expression levels of T-cell receptor Vγ2 and the anti-tuberculosis cytokines interferon γ (IFN-γ) and interleukin 17A (IL-17A). D, Representative flow cytometry-based histograms and bar graph data show that transduction with a combination of LV-has-125b-5p and LV-has-337-3p but not controls significantly improved production of IL-17A and IFN-γ by IL-23-expanded, HMBPPstimulated Vγ2Vδ2 T cells from patients with tuberculosis. Data are means ± standard errors of the mean, pooled from 12 patients with tuberculosis in 4 independent experiments. *P < .05 and **P < .01.
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IL-23/HMBPP-costimulated Vγ2Vδ2 T cells as compared to controls ( Figure 6D ). These results therefore support our hypothesis that tuberculosis-driven increases in hsa-125b-5p and hsa-337-3p expression might help to downregulate the STAT3 activation pathway and impair IL-23 signaling for expansion of HMBPP-stimulated Vγ2Vδ2 T cells in patients with tuberculosis.
DISCUSSION
The current study is the first to demonstrate that patients with tuberculosis exhibit selective destruction of the IL-23 signal effect on the HMBPP-specific γδ T-cell subset, with consequent IL-23-targeted exhaustion of Vγ2Vδ2 T-cell responses. Such selective impairment of the effect of IL-23 signaling can be linked to depressed expression and phosphorylation of STAT3, as well as to overexpression of the antagonizing factor SOCS3. Downregulation of the STAT3 signaling pathway in Vγ2Vδ2 T cells correlates with remarkable increases in 2 miRNAs targeting STAT3. Silence of these miRNAs by miRNA sponges can improve the IL-23-induced expansion and function of HMBPPstimulated Vγ2Vδ2 T cells from patients with tuberculosis. Thus, these findings support the compelling hypothesis that tuberculosis can impair the signaling pathway of a selected cytokine and consequently exhaust antigen-specific T cells.
IL-23-mediated expansion of HMBPP-stimulated Vγ2Vδ2 T cells can clearly be demonstrated in subjects with LTBI or a BCG vaccination history. This result in humans appears to be consistent with our previous report demonstrating recall-like expansion of Vγ2Vδ2 T cells induced by Th17-related cytokines, including IL-23, in macaques after primary M. tuberculosis infection or vaccination [18] . Our new data from humans suggest that IL-23 and IL-2 significantly expand HMBPPstimulated Vγ2Vδ2 T cells. Results from IL-2-blockade and transient HMBPP activation models demonstrate that IL-2 synergizes or facilitates IL-23-induced expansion of Vγ2Vδ2 T cells but that IL-2 blockade cannot totally abrogate the IL-23-induced expansion. This is also supported by STAT3 blockade data demonstrating that STAT3 is involved in the expansion of Vγ2Vδ2 T cells by IL-23 but not IL-2.
It is interesting that tuberculosis can selectively impair IL-23 signaling but spare the effect of IL-2 on Vγ2Vδ2 T cells. Such selective impairment of the effect of IL-23 is relative to IL-2 sparing, and further studies may uncover broad destruction of other cytokines′ signals, involving other immune cells, during tuberculosis or other infections. Selective impairment of the effect of IL-23 signaling is implicative because Vγ2Vδ2 T cells in patients with tuberculosis exhibit lower levels of STAT3 expression and phosphorylation [40] . These changes may be interrelated with the impairment of the effect of IL-23, although a precise cause and effect associated with these changes is currently unclear. Such selective impairment of IL-23 effect may occur as a result of persistent exposure of Vγ2Vδ2 T cells to HMBPP or IL-23 during chronic M. tuberculosis infection [41] . Since STAT3 is involved in IL-23-induced expansion of Vγ2Vδ2 T cells, it is not surprising that inadequate levels of STAT3 expression and phosphorylation would impair the IL-23-mediated expansion of these γδ T cells. It is also reasonable that IL-2 can still adequately expand HMBPP-stimulated Vγ2Vδ2 T cells, because IL-2 uses signaling pathways other than STAT3 [42] .
Tuberculosis-driven impairing of IL-23-induced expansion of Vγ2Vδ2 T cells appears to be different from T-cell exhaustion linked to PD-1 signaling. Upregulation of PD-1 has been shown to correlate with T-cell exhaustion in cancers and viral infection [5] , although functional aspects of PD-1 expression in M. tuberculosis infection remain to be solved [3] . Here, we show that tuberculosis impairs the effect of IL-23/STAT3 signaling on Vγ2Vδ2 T cells. While blockade of the PD-1 pathway by antibody can reverse the exhaustion of αβ T cells linked to PD-1 expression [43] , such a blockade cannot restore IL-23-induced expansion of Vγ2Vδ2 T cells, despite our use of 2 different sources of PD-1 antibodies capable of recovering from T-cell exhaustion [23, 24] .
Remarkable increases in STAT3-targeted miRNAs in Vγ2Vδ2 T cells may help to explain the selective impairment of IL-23-mediated expansion of Vγ2Vδ2 T cells in patients with tuberculosis. Vγ2Vδ2 T cells in patients with tuberculosis display greater expression of 4 miRNAs that have been shown to negatively regulate STAT3 activation or phosphorylation [39] . Among them, hsa-miR-337-3p and hsa-miRNA-125b-5p are expressed significantly higher during tuberculosis than in BCG-vaccinated HCs. Most strikingly, downregulation of hsamiR-337-3p and hsa-miRNA-125b-5p by using an miRNA sponge allows for detectable recovery of IL-23-induced expansion of Vγ2Vδ2 T cells in patients with tuberculosis, as well as the effector function of these cells for producing the antituberculosis cytokines IFN-γ and IL-17A.
Thus, we demonstrate that tuberculosis can selectively destroy IL-23-induced expansion of Vγ2Vδ2 T cells. Such selective destruction appears to be linked to the following interrelated mechanistic changes in Vγ2Vδ2 T cells: (1) remarkable upregulation of STAT3-targeted miRNAs, (2) lower expression and phosphorylation of STAT3, and (3) reciprocal overexpression of the regulatory factor SOCS3, thereby inhibiting STAT3 phosphorylation. Tuberculosis-driven upregulation of STAT3-targeted miRNAs may be one of the driving factors, since silencing of them can restore IL-23-mediated expansion and cytokine production. 
